BC Global Opportunities IX LP and Others Report 5.51% Ownership in BridgeBio Oncology Therapeutics, Inc.

BC Global Opportunities IX LP, BC General Partner, LP, BC Capital Management Limited, and Tan Kuangming have collectively reported a 5.51% ownership in BridgeBio Oncology Therapeutics, Inc. The filing, submitted under Rule 13d-1(c), indicates that each entity holds 4,365,747 shares of common stock. The shares are held with shared voting and dispositive power, meaning no single entity has sole control over the shares. The filing also certifies that the securities were not acquired for the purpose of influencing the control of the issuer. The reporting persons are based in the British Virgin Islands and Hong Kong. The filing is of medium importance as it provides transparency regarding significant ownership stakes in the company.